Standard Therapeutic Approach

  • Roberto Mangiarotti
Part of the Updates in Surgery book series (UPDATESSURG)


Crohn’s disease (CD) is characterized by patchy, transmural inflammation that may affect any part of the gastrointestinal tract. It may be defined by location (distal ileum, colonic, ileocolic, upper gastrointestinal) or by pattern of disease (inflammatory, fistulizing, or stricturing). Both these aspects have been combined in the Vienna classification. CD may cause intestinal obstruction due to strictures, fistulae (often perianal), or abscesses, and the clinical course of the disease is characterized by exacerbations and remission. Therapy for inflammatory bowel disease (IBD) is a rapidly evolving field, with the many new biological agents under investigation likely to change therapeutic strategies in the future. The general approach for treating active CD must consider the degree of activity, location, and behavior of the disease, including its course, response to previous medications, side effects of medication, and possible presence of extraintestinal manifestations). In this chapter, the principal drugs employed as a first-line treatment are discussed.


Ileocolic Resection Thiopurine Therapy Standard Therapeutic Approach Simple Perianal Fistula 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sandborn WJ, Hanauer SB (2003) Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine prodrugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17:29–42CrossRefPubMedGoogle Scholar
  2. 2.
    Prantera C, Cottone M, Pallone F et al (1999) Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized multicenter trial. Gastroenterology 116:521–526CrossRefPubMedGoogle Scholar
  3. 3.
    Lochs H, Mayer M, Fleig WE et al (2000) Prophylaxis of post-operative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 118:264–273CrossRefPubMedGoogle Scholar
  4. 4.
    van Staa T P, Travis S P L, Leufkens H J M et al (2004) 5-aminosalicylic acids and the risk of renal disease: a large British epidemiological study. Gastroenterology 126:1733–1739CrossRefPubMedGoogle Scholar
  5. 5.
    Franchimont D, Kino T, Galon J et al (2003) Glucorticoids and inflammation revisited: the state of the art. Neuro immunomodulation 10:247–260Google Scholar
  6. 6.
    Summers RW, Switz DM, Sessions JT et al (1979) National co-operative Crohn’s disease study group: results of drug treatment. Gastroenterology 77:847–869PubMedGoogle Scholar
  7. 7.
    Steinhart AH, Ewe K, Griffiths AM et al (2001) Corticosteroids for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev (3) CD000301Google Scholar
  8. 8.
    Sandborn W, Sutherland L, Pearson D et al (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev (2): CD000545Google Scholar
  9. 9.
    Lemann M, Bouhnik Y, Colombel J et al (2002) Randomized, double-blind, placebo-controlled, multicentre, azathioprine withdrawal trial in Crohn’s disease. Gastroenterology 122:A23Google Scholar
  10. 10.
    Colombel JF, Ferrari N, Debuysere H et al (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118:1025–1030CrossRefPubMedGoogle Scholar
  11. 11.
    Fraser AG (2003) Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol 15:225–231CrossRefPubMedGoogle Scholar
  12. 12.
    Alfadhli AA, McDonald JW, Feagan BG (2003) Methotrexate for induction of remission in refractory Crohn’s disease (Cochrane Review). Cochrane Database Syst Rev (1):CD003459Google Scholar
  13. 13.
    Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632CrossRefPubMedGoogle Scholar
  14. 14.
    Feagan BG, McDonald JW, Rochon J et al (1994) Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med 330:1846–1851CrossRefPubMedGoogle Scholar
  15. 15.
    Feagan BG (1995) Cyclosporin has no proven role as a therapy for Crohn’s disease. Inflamm Bowel Dis 1:335–339CrossRefGoogle Scholar
  16. 16.
    Egan LJ, Sandborn WJ, Tremaine WJ (1998) Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol 93:442–448CrossRefPubMedGoogle Scholar
  17. 17.
    Sandborn WJ, Present DH, Isaacs K L et al (2003) Tacrolimus for the treatment of fistulas in patients with Crohn’s disease. Gastroenterology 125:380–388CrossRefPubMedGoogle Scholar
  18. 18.
    Sasaki M, Sitaraman SV, Babbin BA et al (2007) Invasive Escherichia coli are a feature of Crohn’s disease. Lab Invest 87:1042–1054CrossRefPubMedGoogle Scholar
  19. 19.
    Prantera C, Scribano ML (2009) Antibiotics and probiotics in inflammatory bowel disease why, when, and how. Curr Opin Gastroenterol 25:329–333CrossRefPubMedGoogle Scholar
  20. 20.
    Prantera C, Zannoni F, Scribano M L et al (1996) An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 91:328–332PubMedGoogle Scholar
  21. 21.
    Prantera C, Lochs H, Campieri M et al (2006) Antibiotic treatment of Crohn’s disease: results of a multicentre, double-blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 23:1117–1125CrossRefPubMedGoogle Scholar
  22. 22.
    Stange EF, Travis SPL, S Vermeire S et al for the European Crohn’s and Colitis Organisation (ECCO) (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis Gut 55 (Supplement 1): i1–i15CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2010

Authors and Affiliations

  • Roberto Mangiarotti
    • 1
  1. 1.Gastroenterology UnitSan Camillo-Forlanini HospitalRomeItaly

Personalised recommendations